The Hepatitis C market was worth $2.3 billion in 2007, declining at a CAGR of -2.8% from 2004-2007. Despite this recent slump, sales are forecast to grow to $4.5 billion by 2017, driven primarily by the launch of the new protease inhibitors. The US and EU will remain the largest markets, generating $1.9 billion and $1.7 billion respectively in 2017.
Key reasons to purchase this title
- Understand current and future Hepatitis C market dynamics - Gain insight into the unmet needs of HCV patients and the extent to which pipeline drugs are addressing these issues - Assess current and future market size and the impact of new drug launches
This product contains forecasts for hepatitis C across the seven major markets from 2007 to 2018. It has been designed for delivery in an excel data pack format.
